

## AMENDMENT

### In the Claims

This listing of claims will replace all prior versions and listings of claims.

1-26. (Canceled)

27. (Currently Amended) A method for delivery of one or more ~~than one~~ cytokines ~~biologically-active factors~~ comprising administering to a human or animal a composition comprising one or more cytokines ~~than one biologically-active factors~~ and a target molecule admixed with or bound to a colloidal metal.

28. (Currently Amended) The method of Claim 27, wherein the one or more cytokines are ~~biologically-active factor~~ is selected from the group consisting of Interleukin-1a ("IL-1a"), Interleukin-1B ("IL-1 $\beta$ "), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), ~~lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B,~~ Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, and Granulocyte CSF, ~~vaseular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF $\alpha$ "), transforming growth factor beta ("TGF  $\beta$ "), heat shock proteins, carbohydrate moieties of blood groups, RH factors, fibroblast growth factor, chemotherapeutic drugs, AZT, nucleotides, DNA, RNA, sense, antisense, cancer, cell specific antigens, hormones, antibodies, and immunotherapeutic drugs.~~

29. (Currently Amended) A method for the targeted delivery of one or more chemotherapeutic agents ~~biologicall-active factors~~, comprising administering to a human or animal a composition comprising one two or more chemotherapeutic agents and a target molecule ~~biologically-active factors~~ admixed with or bound to colloidal metal, wherein ~~at least one of the biologically active factors admixed with or bound to colloidal metal wherein at least one of the biologically active factors is a target molecule capable of binding a receptor on a cell membrane and wherein at least one of the biologically active factors is released from the composition in vivo.~~
30. (Currently Amended) A method of the delivering one or more biological factors comprising administering to a human or animal a composition comprising one or more biologically active factors and a target molecule admixed with or bound to a colloidal metal, wherein the biologically active factor is selected from the group consisting of ~~The method of Claim 29, wherein the biologically active factor is selected from the group consisting of~~ Interleukin-1a ("IL-1 $\alpha$ "), Interleukin-1B ("IL-1 $\beta$ "), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage-CSF, Granulocyte-CSF, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF $\alpha$ "), transforming growth factor beta ("TGF  $\beta$ "), heat shock proteins, carbohydrate moieties of blood groups, RH factors, fibroblast growth factor, ~~chemotherapeutic drugs, AZT, nucleotides, DNA, RNA, sense, antisense, cancer[,]~~ cell specific antigens, hormones, antibodies, antibiotics, anti-virals and immunotherapeutic drugs.

31. (Currently Amended) The method of Claim 27[29], wherein the target molecule is selected from the group consisting of Interleukin-1a (“IL-1a”), Interleukin-1B (“IL-1β”), Interleukin-2 (“IL-2”), Interleukin-3 (“IL-3”), Interleukin-4 (“IL-4”), Interleukin-5 (“IL-5”), Interleukin-6 (“IL-6”), Interleukin-7 (“IL-7”), Interleukin-8 (“IL-8”), Interleukin-9 (“IL-9”), Interleukin-10 (“IL-10”), Interleukin-11 (“IL-11”), Interleukin-12 (“IL-12”), Interleukin-13 (“IL-13”), Type I Interferon, Type II Interferon, Tumor Necrosis Factor (“TNFa”) Transforming Growth Factor-β (“TGFβ”), Migration Inhibition Factor, vascular epithelial growth factor (“VEGF”), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polyclonal antibodies, cancer cell specific antigen, and transforming growth factor alpha (“TGFa”).

32-34. (Canceled)

35. (Currently Amended) The method of claim 29[33] wherein the target molecule is selected from the group consisting of Interleukin-1a (“IL-1a”), Interleukin-1B (“IL-1β”), Interleukin-2 (“IL-2”), Interleukin-3 (“IL-3”), Interleukin-4 (“IL-4”), Interleukin-5 (“IL-5”), Interleukin-6 (“IL-6”), Interleukin-7 (“IL-7”), Interleukin-8 (“IL-8”), Interleukin-9 (“IL-9”), Interleukin-10 (“IL-10”), Interleukin-11 (“IL-11”), Interleukin-12 (“IL-12”), Interleukin-13 (“IL-13”), Type I Interferon, Type II Interferon, Tumor Necrosis Factor (“TNFa”) Transforming Growth Factor-β (“TGFβ”), Migration Inhibition Factor, vascular epithelial growth factor (“VEGF”), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polyclonal antibodies, cancer cell specific antigens, and transforming growth factor alpha (“TGFa”).

36. (New) The method of claim 35, wherein the target molecule is TNFa.

37. (New) The method of claim 35, wherein the target molecule is a cancer cell specific antigen.

38. (New) The method of claim 37, wherein the cancer cell specific antigen is MART, MAGE, or BAGE.
39. (New) The method of claim 35, wherein the targeting molecule is a polyclonal or monoclonal antibody.
40. (New) The method of claim 31, wherein the target molecule is a cancer cell specific antigen.
41. (New) The method of claim 41, wherein the cancer cell specific antigen is MART, MAGE, or BAGE.
42. (New) The method of claim 31, wherein the target molecule is a polyclonal or monoclonal antibody.
43. (New) The method of claim 30, wherein the target molecule is selected from the group consisting of Interleukin-1a ("IL-1a"), Interleukin-1B ("IL-1 $\beta$ "), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Tumor Necrosis Factor ("TNF $\alpha$ ") Transforming Growth Factor- $\beta$  ("TGF $\beta$ "), Migration Inhibition Factor, vascular epithelial growth factor ("VEGF"), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polyclonal antibodies, a bacterial coat protein, a cancer cell specific antigen, and transforming growth factor alpha ("TGF $\alpha$ ").

44. (New) The method of claim 43, wherein the targeting molecule is TNF $\alpha$ .
45. (New) The method of claim 43, wherein the target molecule is a cancer cell specific antigen.
46. (New) The method of claim 45, wherein the cancer cell specific antigen is MART, MAGE or BAGE.
47. (New) The method of claim 43, wherein the target molecule is IL-2 and the biologically active factor is an anti-viral compound.
48. (New) The method of claim 43, wherein the target molecule is a bacterial coat protein and the biologically active agent is an antibiotic.